• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [19518 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2008     NIHR Health Technology Assessment programme 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis
1999     NIHR Health Technology Assessment programme 'Early warning systems' for identifying new healthcare technologies
2001     Danish Institute for Health Services Research (DSI) 'Health projekc Ebeltoft'. General practitioners valuation of organisational aspects by implementing preventive examination of health and conversation in general practitioner. DSI Rapport 2001.05
2002     Centre for Clinical Effectiveness (CCE) 'Open' versus 'closed' systems for enteral feeding
2000     Alberta Heritage Foundation for Medical Research (AHFMR) 'Soft copy' digital mammography
2003     NIHR Health Technology Assessment programme "CLIP" Central Line Insertion Project, primary research
2005     Israel Center for Technology Assessment in Health Care (ICTAHC) "Publication profile" of an innovative technology - case study: coronary stent (abstract)
2005     Israel Center for Technology Assessment in Health Care (ICTAHC) "Techno-markers" for health technology utilization assessment (abstract)
2000     ECRI (111)In-capromab pendetide for staging prostate cancer in men at high risk of metastasis
2021     Austrian Institute for Health Technology Assessment (AIHTA) (Good) practice organisational models using real-world evidence for public funding of high priced therapies
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018
2018     NIHR Health Technology Assessment programme (REBALANCE) REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis
2012     Basque Office for Health Technology Assessment (OSTEBA) [«BAatera Zainduz»: implementation of chronic disease management models in primary care, focused on the integration of assistance]
2008     Committee for New Health Technology Assessment (CNHTA) [1) PCCA gene, mutation[sequencing] 2) PCCB gene, mutation[sequencing]]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [10th Symposium Health Technology Assessment, Nothing without evidence? 18th-19th March 2010, Cologne]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [11th Symposium Health Technology Assessment, theoretical practice - practical theory? 17th to 18th March 2011, Cologne]
2010     Committee for New Health Technology Assessment (CNHTA) [18-f-sodium fluoride (18-f-naf) bone positron emission tomography, positron emission tomography/computed tomography]
2004     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [18-FDG positron emission tomography in oncology: HTA reports by international HTA agencies]
2021     Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2010     Finnish Office for Health Care Technology Assessment (Finohta) [18Fluorodeoxyglucose positron emission tomography in the assessment of patients with potentially curable cancer]
2012     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [1st Expert Panel on viper venomous bite in Spain]
2007     Andalusian Health Technology Assessment Area (AETSA) [3 Tesla Magnetic Resonance Imaging]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [3D Echocardiography in heart valve diseases]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [4CMenB vaccine for primary vaccination]
2010     Andalusian Health Technology Assessment Area (AETSA) [4D Ultrasound]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [8th Symposium Health Technology Assessment - Decision-making in medicine, 2007, October 18 - 19, Cologne]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [9th Symposium Health Technology Assessment - Patients in no man's land, 2008, October 17 - 18, Cologne]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A classification algorithm for low back pain: matching patients to treatments that they are most likely to benefit from]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A construction of support scheme for health technology evidence-generation in Korea]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [A controlled trial of geriatric liaison intervention in frail surgical oncology patients]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A health technology assessment of the effectiveness and safety of robot surgery]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [A health technology evaluation study for reviewing possibility of data linkage]
2011     Haute Autorite de sante (HAS) [A priori evaluation of the expansion of newborn screening to one or more inborn error(s) of metabolism using the technology of tandem mass spectrometry in the general population in France. Part 1: medium chain CoA dehydrogenase deficiency (MCADD)]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A prospective, randomised controlled trial comparing in-hospital treatment and early assisted discharge for exacerbations of chronic obstructive pulmonary disease (COPD)]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomised controlled trial comparing the cost-effectiveness of pelvic floor muscle exercise versus the TVT (O) procedure for female moderate to severe stress urinary incontinence]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomised controlled trial in the palliative setting regarding off-label medication: investigating the efficiency of amitriptyline versus pregabalin from a societal perspective]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomised cost-effectiveness study on the surgical versus conservative treatment of sciatica]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomized clinical trial of urinary incontinence in older women: cost-effectiveness of protocolized assessment and evidence-based treatment]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomized controlled trial to assess the effectiveness of aspirin and anticoagulant treatment in women with unexplained recurrent miscarriage: ALIFE study (anticoagulants for living fetuses)]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A research on evidence-based healthcare for thyroid cancer screening. Part 1 : the current status of thyroid cancer screening]
2013     Andalusian Health Technology Assessment Area (AETSA) [A review of indications for ventricular assist device therapy]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study of high-risk dyslipidemia for cardiocerebrovascular disease in Koreans]
2007     Center for Medical Technology Assessment (CMT) [A study of principles of compensation for health care services]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [A study of the effectiveness of self-care interventions for subclinical and mild depression]
2013     Basque Office for Health Technology Assessment (OSTEBA) [A study of the use of clinical practice guidelines in specialized care: barriers and facilitators to implementation]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on current issues of hearing aid use in Korean patients with hearing loss]
2010     Andalusian Health Technology Assessment Area (AETSA) [A study on efficacy, effectivity and efficiency of Intensity Modulated Radiotherapy (IMRT). Utility for treatment of breast and central nervous system neoplasms and sarcomas of bones and soft tissue]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on Korean adolescents' risk factors of suicide]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the evaluation standards of osteoporosis in Korea]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the factors influencing adherence to antidepressant therapies and the cost-effectiveness of antidepressant therapies in Korea]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the system and execution model for health technology reassessment]
2021     Center for Drug Evaluation (CDE) [A systematic review of the comparative efficacy and cost-effectiveness of current listed statins in Taiwan]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A systematic review of the diagnostic accuracy of FDG PET/PET-CT for fever of unknown origin]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [A16-05 dabrafenib/trametinib - addendum to commissions A15-39 and A15-40]
2009     Committee for New Health Technology Assessment (CNHTA) [AB0-Rh(D) blood grouping automation test using CAT (column agglutination technology)]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Abemaciclib, palbociclib and ribociclib in breast cancer]
2011     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (New therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2011     Finnish Office for Health Care Technology Assessment (Finohta) [Ablation therapy of liver tumors]
2008     Committee for New Health Technology Assessment (CNHTA) [Access flow measurement for hemodialysis]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Accuracy and cost-effectiveness of diagnostic testing in patients with abdominal pain in general practice: a decision analysis]
2013     The Netherlands Organisation for Health Research and Development (ZonMw) [Accuracy and cost-effectiveness of two clinical decision rules for the diagnosis of deep vein thrombosis and pulmonary embolism in residents of nursing homes and homes for the elderly]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Accuracy of FDG-PET and spiral CT for the early prediction of non-response to preoperative chemoradiotherapy in patients with esophageal cancer]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [ACCURATE: Asthma Control Cost-Utility RAndomized Trial Evaluation Goals of asthma treatment: how high should we go?]
2009     Committee for New Health Technology Assessment (CNHTA) [Acellular dermal graft]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium bromide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium bromide - benefit assessment according to §35a Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aclidinium/formoterol: benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Andalusian Health Technology Assessment Area (AETSA) [Active immunotherapy for breast cancer]
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Active knee motion devices in the treatment of anterior cruciate ligament ruptures]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [Activity, Lifestyle, and Nutrition and Therapy study (ALANT study)]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Actualization: radiofrequency sympathetic denervation of the renal arteries for refractory arterial hypertension]
2014     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Acupuncture - areas of application, current evidence and proven indications]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for carpal tunnel syndrome]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for headache]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for lateral epicondylitis]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Acupuncture for treating lumbago]
2016     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Acute neck and back pain: preventive interventions – effects of physical training, manual treatment and cognitive behavioral interventions]
2013     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Acute pain treatment on postoperative and medical non-surgical wards]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Adalimumab for treating rheumatoid arthritis]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis]
2009     Committee for New Health Technology Assessment (CNHTA) [ADAMTS 13 Activity]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Adaptation and assessment of an online research methodology training course for nurses]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Adaptation to the Catalan health care system of the clinical practice guideline 'Management of major depression in adults']
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-15 Crizotinib]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A12-16 Saxagliptin/metformin]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-03 (sitagliptin/metformin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-05 (fidaxomicin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-06 (abiraterone acetate [new therapeutic indication])]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-09 (vandetanib)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-10 (pertuzumab)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-16 (vildagliptin)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to commission A13-17 (vildagliptin/metformin)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-33 (enzalutamide)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-35 (dabrafenib)]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A13-37 (regorafenib)]